Skip Nav Destination
Issues
15 June 2008
-
Cover Image
Cover Image
A colon cancer tissue microarray containing 583 stage I-IV patients was stained for pan-cadherin, DAPI, and Met protein. Using novel automated curvature and intensity-based image analysis, epithelial membrane (red), cytoplasm (green) and nuclei (blue) were segmented. Stromal nuclei are shown in gray. The probability distribution of Met protein within each compartment was determined. A higher distribution of Met in the cytoplasm relative to the membrane was a significant predictor of survival in stage I and II patients. For further details, please see Ginty and colleagues on page 3814 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Commentary
CCR Practice of Translational Oncology
Molecular Pathways
CCR Focus
Designing Phase 0 Cancer Clinical Trials
Anthony J. Murgo; Shivaani Kummar; Larry Rubinstein; Martin Gutierrez; Jerry Collins; Robert Kinders; Ralph E. Parchment; Jiuping Ji; Seth M. Steinberg; Sherry X. Yang; Melinda Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Joseph E. Tomaszewski; James H. Doroshow
Review
Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions
Sabina Signoretti; Gennady Bratslavsky; Frederick M. Waldman; Victor E. Reuter; John Haaga; Maria Merino; George V. Thomas; Michael R. Pins; Towia Libermann; John Gillespie; Joseph E. Tomaszewski; Carolyn C. Compton; Andrew Hruszkewycz; W. Marston Linehan; Michael B. Atkins
Human Cancer Biology
ssDNA-Binding Protein 2 Is Frequently Hypermethylated and Suppresses Cell Growth in Human Prostate Cancer
Jun-Wei Liu; Jatin K. Nagpal; Wenyue Sun; Juna Lee; Myoung Sook Kim; Kimberly L. Ostrow; Shaoyu Zhou; Carmen Jeronimo; Rui Henrique; Wim Van Criekinge; Chu So Moon; Joseph A. Califano; Barry Trink; David Sidransky
Down-Regulation of Hedgehog-Interacting Protein through Genetic and Epigenetic Alterations in Human Hepatocellular Carcinoma
Motohisa Tada; Fumihiko Kanai; Yasuo Tanaka; Keisuke Tateishi; Miki Ohta; Yoshinari Asaoka; Motoko Seto; Ryosuke Muroyama; Kenichi Fukai; Fumio Imazeki; Takao Kawabe; Osamu Yokosuka; Masao Omata
Imaging, Diagnosis, Prognosis
Effect of Interleukin-10 Gene Polymorphisms on Clinical Outcome of Patients with Aggressive Non-Hodgkin's Lymphoma: An Exploratory Study
Dieter Kube; Thanh-Duc Hua; Frederike von Bonin; Nils Schoof; Samira Zeynalova; Marita Klöss; Daniela Gocht; Bernd Potthoff; Mladen Tzvetkov; Jürgen Brockmöller; Markus Löffler; Michael Pfreundschuh; Lorenz Trümper
Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection
Xin-Rong Yang; Yang Xu; Guo-Ming Shi; Jia Fan; Jian Zhou; Yuan Ji; Hui-Chuan Sun; Shuang-Jian Qiu; Bing Yu; Qiang Gao; Yi-Zhou He; Weng-Zhen Qin; Rong-Xin Chen; Guo-Huan Yang; Bing Wu; Qing Lu; Zhi-Quan Wu; Zhao-You Tang
Cancer Therapy: Clinical
Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?
Myung-Ju Ahn; Byeong-Bae Park; Jin Seok Ahn; Sang We Kim; Heung-Tae Kim; Jong Seog Lee; Jin Hyung Kang; Jae Yong Cho; Hong Suk Song; Se Hoon Park; Chang Hak Sohn; Sang Won Shin; Jin Hyuck Choi; Chang-Seok Ki; Chan Keum Park; Alison J. Holmes; Pasi A. Jänne; Keunchil Park
A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
Enriqueta Felip; Federico Rojo; Martin Reck; Astrid Heller; Barbara Klughammer; Gemma Sala; Susana Cedres; Sergio Peralta; Heiko Maacke; Dorothee Foernzler; Marta Parera; Joachim Möcks; Cristina Saura; Ulrich Gatzemeier; José Baselga
Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Rebecca B. Klisovic; William Blum; Xiaohui Wei; Shujun Liu; Zhongfa Liu; Zhiliang Xie; Tamara Vukosavljevic; Cheryl Kefauver; LeNguyen Huynh; Jiuxia Pang; James A. Zwiebel; Steven Devine; John C. Byrd; Michael R. Grever; Kenneth Chan; Guido Marcucci
Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity
Taylor Sittler; Jun Zhou; Joosang Park; Noah K. Yuen; Stefanie Sarantopoulos; Joseph Mollick; Ravi Salgia; Anita Giobbie-Hurder; Glenn Dranoff; F. Stephen Hodi
Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Srdan Verstovsek; Ayalew Tefferi; Jorge Cortes; Susan O'Brien; Guillermo Garcia-Manero; Animesh Pardanani; Cem Akin; Stefan Faderl; Taghi Manshouri; Deborah Thomas; Hagop Kantarjian
Cancer Therapy: Preclinical
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
Bastiaan Evers; Rinske Drost; Eva Schut; Michiel de Bruin; Eline van der Burg; Patrick W.B. Derksen; Henne Holstege; Xiaoling Liu; Ellen van Drunen; H. Berna Beverloo; Graeme C.M. Smith; Niall M.B. Martin; Alan Lau; Mark J. O'Connor; Jos Jonkers
DNA-Dependent Protein Kinase Is a Therapeutic Target and an Indicator of Poor Prognosis in B-Cell Chronic Lymphocytic Leukemia
Elaine Willmore; Sarah L. Elliott; Tryfonia Mainou-Fowler; Geoffrey P. Summerfield; Graham H. Jackson; Fran O'Neill; Christopher Lowe; Anthony Carter; Robert Harris; Andrew R. Pettitt; Celine Cano-Soumillac; Roger J. Griffin; Ian G. Cowell; Caroline A. Austin; Barbara W. Durkacz
PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel
Lin Yang; Michelle J. Clarke; Brett L. Carlson; Ann C. Mladek; Mark A. Schroeder; Paul Decker; Wenting Wu; Gaspar J. Kitange; Patrick T. Grogan; Jennie M. Goble; Joon Uhm; Evanthia Galanis; Caterina Giannini; Heidi A. Lane; C. David James; Jann N. Sarkaria
Cancer Prevention and Susceptibility
Phosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors
Rossella Libé; Amato Fratticci; Joel Coste; Frédérique Tissier; Anelia Horvath; Bruno Ragazzon; Fernande Rene-Corail; Lionel Groussin; Xavier Bertagna; Marie Laure Raffin-Sanson; Constantine A. Stratakis; Jérome Bertherat
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.